Alnylam Pharmaceuticals, Inc. (ALNY) financials
NASDAQ · Healthcare · Biotechnology · 2,500 employees · CEO Yvonne L. Greenstreet
- Price
- $165.00 -5.17%
- Market cap
- $22.1B
- Enterprise value
- $21.6B
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-11 EPS est. $1.75
Revenue (TTM)$5.01B+56.2% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)19.5%+11.3 pp vs a year agoOperating income $978M
Net income (TTM)$2.72B+6,153.3% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$501M+126.2% vs a year agoCapex $150M
Diluted EPS (TTM)$19.80+8,150.0% vs a year agoSum of the last 4 quarters
Net cash$2.33B+64.2% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $22.1B EV $21.6B
- Revenue
- $5.01B Trailing 12 months
- Revenue growth
- +47% FY2026 consensus
- Profit margin
- 54.3% Net income / revenue, TTM
- P/E
- 8.1× Forward 9.3× (FY2026)
- P/S
- 4.4× Price / sales, TTM
- EV / EBITDA
- 17.3× TTM
- Free cash flow
- $501M Trailing 12 months
- Net income
- $2.72B Trailing 12 months
- Revenue estimate
- $5.44B FY2026 consensus
- Earnings
- 2027-02-11 Revenue est. $1.53B
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-10-29): revenue beat by 1.9%, EPS beat by 879.5%Revenue $1.46B vs $1.43B expected (+1.9%); EPS $16.26 vs $1.66 (+879.5%).
- Revenue growth slowing: 16.7% year on yearQ3 '26 revenue $1.46B, against an average of 99.4% over the four quarters before.
- Operating margin 19.5% (TTM), +11.3 pp on a year agoOperating income grew 269.3% while revenue grew 56.2%.
- 14.2% of pre-tax profit is eaten by non-operating lossesPre-tax income $856M vs operating income $978M (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
- Capex 3.0% of revenue (a year ago 1.4%)$150M invested in the last 4 quarters (+236.3% on a year earlier). Free cash flow $501M = 18.4% of net income.
- Diluted share count up 0.5% in a year138M diluted shares in Q3 '26, 137M a year earlier.
- Net cash $2.33BCash + short-term investments $3.59B, debt incl. leases $1.26B; a year ago net cash $1.42B.
Last quarter: Q3 '26
Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $1.46B | $1.25B | +16.7% |
| Gross margin | 75.2% | 84.2% | -9.0 pp |
| Operating income | $346M | $368M | -6.0% |
| Operating margin | 23.7% | 29.5% | -5.7 pp |
| Net income | $2.17B | $251M | +763.2% |
| Diluted EPS | $15.72 | $1.84 | +754.3% |
| Operating cash flow | $341M | $325M | +4.9% |
| Capex | $69.8M | $12.1M | +475.1% |
| Free cash flow | $271M | $313M | -13.4% |
| R&D | $409M | $359M | +13.9% |
| Stock-based compensation | $79.1M | $108M | -26.9% |
Reported vs consensus
2026-10-29| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $1.46B | $1.43B | +1.9% |
| EPS (as estimated) | $16.26 | $1.66 | +879.5% |
From the report of 2026-10-29 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q3 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Product | $1.29B | – | 92.2% | – | – | |
| GIVLAARI | $89.5M | – | 6.4% | $414M | – | |
| ONPATTRO | $19.6M | – | 1.4% | $129M | – |
Revenue by region
share of total| Segment | Q3 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| United States | $909M | – | 80.4% | $3.59B | – | |
| Europe | $131M | – | 11.6% | $596M | – | |
| Non-US Or Europe | $91M | – | 8.1% | $356M | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $650M
- Capex
- -$150M
- Buybacks
- $0
- Dividends
- $0
- Acquisitions
- $0
- Net debt issued
- -$55.8M
- Stock-based compensation
- $308M
- Free cash flow
- $501M
- Returned to shareholders / FCF
- -0.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 8.1× | 166.4× 1 of 5 years | 166.4× – 166.4× |
| EV / EBITDA | 17.3× | 81.9× 1 of 5 years | 81.9× – 81.9× |
| EV / Sales | 4.3× | 18.6× | 13.3× – 28.3× |
| Price / FCF | 44.1× | 341.0× 2 of 5 years | 111.9× – 570.0× |
| Price / Book | 6.1× | 182.6× 3 of 5 years | 34.1× – 447.7× |
| FCF yield | 2.3% | -1.0% | -3.6% – 0.9% |
| Return on invested capital | 15.4% | -10.3% | -27.8% – 13.7% |
| Return on equity | 159.7% | 78.9% | -414.6% – 714.9% |
Analysts
Consensus target $330.54 (+100.3%)
range $225.00 – $455.00 · rating Buy
Strong buy0
Buy38
Hold13
Sell1
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $5.44B | +46.5% | $17.81 | +664.4% | 9.3× | 14 |
| FY2027 | $6.66B | +22.3% | $9.19 | -48.4% | 18.0× | 16 |
| FY2028 | $7.9B | +18.7% | $11.47 | +24.8% | 14.4× | 17 |
| FY2029 | $8.97B | +13.4% | $12.92 | +12.7% | 12.8× | 12 |
| FY2030 | $9.98B | +11.3% | $15.16 | +17.3% | 10.9× | 7 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 197 figures Alnylam Pharmaceuticals, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $135M | $118M | +15.1% | $116M | $88.4M | +30.9% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $1.08B | $965M | +12.5% | $778M | $405M | +91.8% |
| Accrued Liabilities, Current | $1.24B | $1.15B | +7.2% | $1.08B | $794M | +36.1% |
| Accrued Professional Fees, Current | $34.3M2025-12-31 | $20M | +71.9% | $34.3M | $20M | +71.9% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $323M2025-12-31 | $270M | +19.4% | $323M | $270M | +19.4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$44.7M | -$21.8M | -105.1% | -$20.1M | -$34.5M | +41.8% |
| Additional Paid in Capital, Common Stock | $7.81B | $7.41B | +5.4% | $7.51B | $7.39B | +1.7% |
| Advertising Expense | – | – | – | $36M | $29.7M | +21.2% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1.36M | 1.79M | -24.2% | 3.36M | 11.4M | -70.6% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $80.2M | $109M | -26.6% | $353M | $275M | +28.1% |
| Assets | $7.99B | $4.85B | +64.8% | $4.97B | $4.24B | +17.1% |
| Assets, Current | $5.11B | $3.95B | +29.3% | $4.05B | $3.3B | +22.9% |
| Assets, Fair Value Disclosure | $2.05B | – | – | $1.42B | $1.99B | -28.8% |
| Capital Expenditures Incurred but Not yet Paid | $5.2M | $5.52M | -5.9% | $10.9M | $2.32M | +369.1% |
| Capitalized Contract Cost, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Cash and Cash Equivalents, at Carrying Value | $1.75B | $1.49B | +17.7% | $1.66B | $966M | +71.5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $44.2M | $25M | +76.7% | $23.6M | $69.1M | -65.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.76B | $1.49B | +17.6% | $1.66B | $969M | +71.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $1.49B2025-09-30 | $1.1B | +35.4% | $869M2022-12-31 | $822M | +5.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $46.3M | $377M | -87.7% | $690M | $154M | +348.8% |
| Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | 0.0% | $0.01 | $0.01 | 0.0% |
| Common Stock, Shares Authorized | 250M | 250M | 0.0% | 250M | 250M | 0.0% |
| Common Stock, Shares, Issued | 134M | 132M | +1.6% | 132M | 129M | +2.4% |
| Common Stock, Shares, Outstanding | 134M | 132M | +1.6% | 132M | 129M | +2.4% |
| Common Stock, Value, Issued | $1.34M | $1.32M | +1.6% | $1.32M | $1.29M | +2.4% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $2.15B | $301M | +616.2% | $328M | -$289M | +213.4% |
| Contract with Customer, Liability, Current | $11.7M | $2.54M | +359.2% | $4.85M | $55.5M | -91.3% |
| Contract with Customer, Liability, Revenue Recognized | $4M | $12.5M | -68.0% | $53.8M | $267M | -79.8% |
| Convertible Debt, Current | $362M | – | – | – | – | – |
| Convertible Debt, Noncurrent | $651M | $1.04B | -37.4% | $1.01B | $1.02B | -1.6% |
| Cost of Goods and Services Sold | $362M | $197M | +83.4% | $677M | $307M | +120.9% |
| Costs and Expenses | $1.11B | $881M | +26.2% | $3.21B | $2.43B | +32.5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $9.67M | $5.94M | +62.7% |
| Current Income Tax Expense (Benefit) | – | – | – | $11.6M | $7.54M | +53.8% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $1.93M | $1.6M | +20.9% |
| Debt Instrument, Interest Rate, Stated Percentage | 10.0%2025-12-31 | 10.0% | 0.0% | 10.0% | 10.0% | 0.0% |
| Debt Securities, Available-for-sale | $1.26B2025-09-30 | $1.68B | -25.1% | $1.79B2024-12-31 | $1.65B | +8.4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $3.46M2025-09-30 | $6.48M | -46.6% | $2.72M2024-12-31 | $3.03M | -10.2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $94K2025-09-30 | $146K | -35.6% | $1.18M2024-12-31 | $1.48M | -20.5% |
| Debt Securities, Available-for-sale, Amortized Cost | $1.26B2025-09-30 | $1.67B | -25.0% | $1.79B2024-12-31 | $1.65B | +8.5% |
| Debt Securities, Available-for-sale, Current | $1.83B | $1.23B | +48.5% | $1.25B | $1.72B | -27.3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$2.2M | -$107M | +97.9% |
| Deferred Income Tax Assets, Net | $2.01B | $98.6M | +1,936.0% | $126M | $117M | +7.8% |
| Deferred Income Tax Expense (Benefit) | -$1.89B | $5.6M | -33,946.6% | -$2.2M | -$107M | +97.9% |
| Deferred Tax Assets, Deferred Income | $1.22M2025-12-31 | $14.5M | -91.6% | $1.22M | $14.5M | -91.6% |
| Deferred Tax Assets, Derivative Instruments | $02025-12-31 | $108M | -100.0% | $0 | $108M | -100.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $594M2025-12-31 | $634M | -6.4% | $594M | $634M | -6.4% |
| Deferred Tax Assets, Gross | $2.92B2025-12-31 | $2.97B | -1.7% | $2.92B | $2.97B | -1.7% |
| Deferred Tax Assets, Net | $126M2025-12-31 | $117M | +7.8% | $126M | $117M | +7.8% |
| Deferred Tax Assets, Operating Loss Carryforwards | $987M2025-12-31 | $883M | +11.8% | $987M | $883M | +11.8% |
| Deferred Tax Assets, Other | $90.6M2025-12-31 | $86.4M | +4.9% | $90.6M | $86.4M | +4.9% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $452M2025-12-31 | $392M | +15.5% | $452M | $392M | +15.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $70M2025-12-31 | $62.1M | +12.7% | $70M | $62.1M | +12.7% |
| Deferred Tax Assets, Valuation Allowance | $2.73B2025-12-31 | $2.79B | -2.0% | $2.73B | $2.79B | -2.0% |
| Deferred Tax Liabilities, Leasing Arrangements | $41.8M2025-12-31 | $41.2M | +1.5% | $41.8M | $41.2M | +1.5% |
| Deferred Tax Liabilities, Other Comprehensive Income | $02025-12-31 | $2.04M | -100.0% | $0 | $2.04M | -100.0% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $17.4M2025-12-31 | $18.6M | -6.6% | $17.4M | $18.6M | -6.6% |
| Depreciation | – | – | – | $54.8M | $55.1M | -0.5% |
| Depreciation, Amortization and Accretion, Net | $14.5M | $13.8M | +4.9% | $55.7M | $56.7M | -1.8% |
| Derivative Liability | – | – | – | $487M2024-12-31 | – | – |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-02